United Therapeutics Corp (UTHR)
367.36
+3.03
(+0.83%)
USD |
NASDAQ |
Nov 21, 16:00
367.86
+0.50
(+0.14%)
After-Hours: 20:00
United Therapeutics Enterprise Value: 13.47B for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 13.47B |
| November 20, 2024 | 13.34B |
| November 19, 2024 | 13.18B |
| November 18, 2024 | 13.11B |
| November 15, 2024 | 13.29B |
| November 14, 2024 | 14.32B |
| November 13, 2024 | 14.95B |
| November 12, 2024 | 14.97B |
| November 11, 2024 | 14.95B |
| November 08, 2024 | 15.38B |
| November 07, 2024 | 15.05B |
| November 06, 2024 | 14.82B |
| November 05, 2024 | 14.16B |
| November 04, 2024 | 13.90B |
| November 01, 2024 | 13.77B |
| October 31, 2024 | 13.77B |
| October 30, 2024 | 13.21B |
| October 29, 2024 | 12.82B |
| October 28, 2024 | 12.69B |
| October 25, 2024 | 12.64B |
| October 24, 2024 | 12.71B |
| October 23, 2024 | 12.81B |
| October 22, 2024 | 13.59B |
| October 21, 2024 | 13.61B |
| October 18, 2024 | 13.51B |
| Date | Value |
|---|---|
| October 17, 2024 | 13.71B |
| October 16, 2024 | 13.58B |
| October 15, 2024 | 13.12B |
| October 14, 2024 | 13.01B |
| October 11, 2024 | 13.06B |
| October 10, 2024 | 12.88B |
| October 09, 2024 | 12.99B |
| October 08, 2024 | 12.95B |
| October 07, 2024 | 12.68B |
| October 04, 2024 | 12.95B |
| October 03, 2024 | 12.69B |
| October 02, 2024 | 12.80B |
| October 01, 2024 | 13.04B |
| September 30, 2024 | 13.06B |
| September 27, 2024 | 13.48B |
| September 26, 2024 | 13.44B |
| September 25, 2024 | 13.52B |
| September 24, 2024 | 13.45B |
| September 23, 2024 | 13.35B |
| September 20, 2024 | 13.23B |
| September 19, 2024 | 13.16B |
| September 18, 2024 | 12.77B |
| September 17, 2024 | 12.88B |
| September 16, 2024 | 12.88B |
| September 13, 2024 | 12.62B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
2.848B
Minimum
Mar 18 2020
15.38B
Maximum
Nov 08 2024
7.762B
Average
8.019B
Median
Feb 14 2022
Enterprise Value Benchmarks
| Liquidia Corp | 654.69M |
| Pfizer Inc | 199.35B |
| Tonix Pharmaceuticals Holding Corp | 17.92M |
| Ardelyx Inc | 1.123B |
| Cingulate Inc | 4.897M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 309.10M |
| Revenue (Quarterly) | 748.90M |
| Total Expenses (Quarterly) | 340.70M |
| EPS Diluted (Quarterly) | 6.39 |
| Gross Profit Margin (Quarterly) | 88.90% |
| Profit Margin (Quarterly) | 41.27% |
| Earnings Yield | 6.20% |
| Operating Earnings Yield | 7.48% |
| Normalized Earnings Yield | 6.490 |